Mostly Cloudy 45°
Tag:

Merck

News
COVID-19: FDA Authorizes Second Antiviral Pill COVID-19: FDA Authorizes Second Antiviral Pill
Covid-19: FDA Authorizes Second Antiviral Pill For the second time in as many days, the Food and Drug Administration (FDA) has authorized the use of an antiviral pill to treat mild and moderate COVID-19 cases. On Thursday, Dec. 23, the FDA approved the use of Merck’s molnupiravir pill for emergency use authorization, a day after officials authorized the use of Pfizer’s COVID-19 treatment pill. Earlier story - COVID-19: FDA OKs First Authorized Home Treatment For Virus Merck’s pill has been cleared for use by adults 18 and older who have tested positive for COVID-19 and are at the greatest risk of being hospitalized or dying from t…

SHARE

by Zak Failla
News
COVID-19: FDA OKs First Authorized Home Treatment For Virus COVID-19: FDA OKs First Authorized Home Treatment For Virus
Covid-19: FDA OKs First Authorized Home Treatment For Virus The fight against COVID-19 took a step forward as federal health officials authorized the first pill that Americans will be able to take at home to head off the worst effects of the virus. On Wednesday, Dec. 22, the US Food and Drug Administration (FDA) granted emergency authorization for Pfizer’s COVID-19 treatment pill, which has been recommended for people at high risk of developing severe cases of COVID-19. The pill could be available as soon as this weekend, according to Pfizer CEO Albert Bourla. Related story - COVID-19: Pfizer Releases Data On Anti-Viral Pill's Effective…

SHARE

by Zak Failla
News
COVID-19: Drugmaker To Seek Emergency Approval For Pill To Treat Virus COVID-19: Drugmaker To Seek Emergency Approval For Pill To Treat Virus
Covid-19: Drugmaker To Seek Emergency Approval For Pill To Treat Virus A new pharmaceutical company is throwing its hat in the ring as the country continues its fight against COVID-19. Merck and Ridgeback Biotherapeutics announced on Friday, Oct. 1 that it is planning to apply for federal emergency approval of a pill that can reportedly help prevent hospitalizations and deaths in COVID-19 patients. According to the company, trials have found that the pill - dubbed molnupiravir - could potentially reduce the risk of hospitalization or death in patients with mild to moderate COVID-19 by approximately 50 percent. The results of the late-stage trial have bee…

SHARE

by Zak Failla
Lifestyle
COVID-19: Little Brown Pill Could Be Difference Maker In Fight Against Virus COVID-19: Little Brown Pill Could Be Difference Maker In Fight Against Virus
Covid-19: Little Brown Pill Could Be Difference Maker In Fight Against Virus Scientists may have cracked the code to help in the fight against COVID-19 and potential future pandemics. Though still in clinical trials, the “little brown pill” molnupiravir may give doctors and researchers a new tool and treatment as the country continues combating the latest wave of COVID-19 cases. Merck (also known as MSD), and Ridgeback Biotherapeutics, LP announced earlier this month that they ran a randomized, double-blind, placebo-controlled trial to evaluate the safety, tolerability, and efficacy of the pill to eliminate the strain that causes COVID-19. According to the prelimin…

SHARE

by Zak Failla